Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective

Zafari, Nima; Velayati, Mahla; Fahim, M.S.; Maftooh, Mina; Pourali, Ghazaleh; Khazaei, Majid; Nassiri, Mohammadreza; Hassanian, Seyed Mahdi; Ferns, Gordon A.; Kiani, Mohammad Ali

doi:10.1016/j.lfs.2022.120760

Cited by 26 publications

(16 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, more and more studies have found that changes in gut microbiota are strongly related to the development of alcoholic liver injury [ 11 ]. Therefore, this study detected and analyzed the effects of different doses of L. plantarum J26 on the gut microbiota of mice with alcoholic liver injury.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Lactobacillus plantarum J26 Alleviating Alcohol-Induced Liver Inflammation by Maintaining the Intestinal Barrier and Regulating MAPK Signaling Pathways

Cheng

Huo

et al. 2022

Nutrients

View full text Add to dashboard Cite

Alcoholic liver disease (ALD), as a global health problem, is mainly caused by liver inflammation. Meanwhile, probiotics have been considered as a potential and promising strategy to prevent and alleviate ALD. This study aimed to investigate the ameliorative effect of pre-intaking with Lactobacillus plantarum J26 (L. plantarum J26) on alcohol-induced liver inflammation, with emphasis on the underlying mechanism for alleviating ALD. The results indicated that L. plantarum J26 could reduce the abundance of Gram-negative pathogenic bacteria by regulating the gut microbiota in mice with alcoholic liver injury, thereby reducing the lipopolysaccharide (LPS) content in the intestine. In addition, L. plantarum J26 could also maintain the intestinal barrier, prevent LPS from crossing the intestinal barrier to correct disorders of the gut–liver axis and then inhibit the activation of Toll-like receptor 4 (TLR4)-mediated MAPK signaling pathway, reducing liver inflammation and restoring liver functions. In conclusion, pre-intake of L. plantarum J26 could alleviate alcohol-induced liver inflammation, which may be closely related to the role of intestinal microbiota in regulating and maintaining the intestinal barrier and then regulating the MAPK signaling pathway.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In recent years, more and more studies have confirmed the role of probiotics in regulating the gut microbiota and maintaining the intestinal barrier [ 9 , 10 , 11 ]. At the same time, probiotics regulation of gut microbiota to alleviate alcohol-induced liver inflammation is a promising potential therapeutic approach [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

Lactobacillus plantarum J26 Alleviating Alcohol-Induced Liver Inflammation by Maintaining the Intestinal Barrier and Regulating MAPK Signaling Pathways

Cheng

Huo

et al. 2022

Nutrients

View full text Add to dashboard Cite

show abstract

“…Ruminococcaceae levels were lower in active drinkers' intestines. 28 Patients with ALD and underlying cirrhosis demonstrated worse dysbiosis than those with non-ALD cirrhosis of comparable severity, highlighting the significant contribution of alcohol to intestinal microbiota dysbiosis. A lower A. muciniphila was linked to more severe ALD.…”

Section: Role Of Gut Microbiota In Liver Diseasementioning

confidence: 94%

Review: Microbial Therapeutics for Liver Disease

Philips,

Augustine

2023

Journal of Gastrointestinal Infections

View full text Add to dashboard Cite

The human gut contains many microorganisms, including bacteria, fungi, viruses, and archaea. Patients with liver disorders have altered intestinal flora and disrupted gut barriers. The role of the gut microbiota in the pathophysiology of many liver disorders is apparent from preclinical models and clinical studies. High-quality studies showed that people with acute or chronic liver disorders of various etiologies, such as non–alcohol- and alcohol-related liver disease, chronic hepatitis virus infection, chronic cholestatic liver disease, and liver cirrhosis and related complications, have less diverse gut flora and associated perturbed microbial functional metabolism. In this review, we discuss unique therapeutic strategies for various liver diseases that involve manipulating the gut microbiota using various methods. We provide a summary of the most recent information on untargeted methods for treating liver illnesses, such as probiotics, prebiotics, and postbiotics, fecal microbiota transplantation, and precision microbiome-centered treatments (e.g., engineered microbes). Recent research suggests that altering the gut microbiota in various ways might slow the onset of liver disease and lessen the associated clinical complications. Growing evidence suggests that antimicrobial therapy with rifaximin can beneficially alter the gut microbiome to reduce hepatic encephalopathy, portal hypertension, and systemic inflammation in decompensated cirrhosis. At the same time, a healthy donor stool transplant improves transplant-free survival in severe alcohol-associated hepatitis, prevents hepatic encephalopathy, and reduces incident and intercurrent infections and multidrug resistance in decompensated cirrhosis.

show abstract

“…Studies have shown that the increased translocation of microorganisms such as Streptococcus , Shuttleworthia , Rothia, and Nubsella in the duodenal mucosa is associated with the early stages of progressive ALD [ 76 ]. In addition, the translocation of the components of intestinal bacteria (e.g., peptidoglycan, LPS, or flagellin) plays an important role in the progression of ALD, with changes in LPS being extensively studied [ 77 , 78 ]. LPS causes endotoxaemia through translocation and interacts with TLR4 in the liver, and the activation of the LPS-TLR4 signalling pathway promotes the release of proinflammatory factors (e.g., TNF-α and IL-6) and exacerbates alcohol-induced liver inflammation [ 70 , 78 ].…”

Section: Pathogenesis Of Aldmentioning

confidence: 99%

Advancements in the Alcohol-Associated Liver Disease Model

Zhu

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Alcohol-associated liver disease (ALD) is an intricate disease that results in a broad spectrum of liver damage. The presentation of ALD can include simple steatosis, steatohepatitis, liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Effective prevention and treatment strategies are urgently required for ALD patients. In previous decades, numerous rodent models were established to investigate the mechanisms of alcohol-associated liver disease and explore therapeutic targets. This review provides a summary of the latest developments in rodent models, including those that involve EtOH administration, which will help us to understand the characteristics and causes of ALD at different stages. In addition, we discuss the pathogenesis of ALD and summarize the existing in vitro models. We analyse the pros and cons of these models and their translational relevance and summarize the insights that have been gained regarding the mechanisms of alcoholic liver injury.

show abstract

Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective

Cited by 26 publications

References 155 publications

Lactobacillus plantarum J26 Alleviating Alcohol-Induced Liver Inflammation by Maintaining the Intestinal Barrier and Regulating MAPK Signaling Pathways

Lactobacillus plantarum J26 Alleviating Alcohol-Induced Liver Inflammation by Maintaining the Intestinal Barrier and Regulating MAPK Signaling Pathways

Review: Microbial Therapeutics for Liver Disease

Advancements in the Alcohol-Associated Liver Disease Model

Contact Info

Product

Resources

About